NDATOPICALCREAM
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
3/8 — Basic
TEMOVATE E (clobetasol propionate) by Sandoz is clinical pharmacology: the corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. First approved in 1994.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEMOVATE E (clobetasol propionate) is a potent topical corticosteroid cream approved in 1994 for treating inflammatory dermatoses including psoriasis, atopic dermatitis, and seborrheic dermatitis. It works via anti-inflammatory, antipruritic, and vasoconstrictive actions on skin, with systemic absorption possible depending on skin barrier integrity and occlusive dressing use.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing or transition to generic defense strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY: The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects. Topical…
Worked on TEMOVATE E at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.